Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | AVPR1B | P47901 | 7/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480290 | 0.95 | MC4R (0.51) | MC4RMCHR1AVPR1BPDE3BPDE3A | |
| SCHEMBL6485221 | 0.95 | MC4R (0.58) | MC4RMCHR1AVPR1BPDE3BPDE3A | |
| SCHEMBL6474588 | 0.94 | MC4R (0.59) | MC4RMCHR1AVPR1BPDE3BPDE3A | |
| SCHEMBL6482608 | 0.93 | AVPR1B (0.55) | MC4RMCHR1AVPR1B | |
| SCHEMBL6485926 | 0.91 | MAOB (0.49) | MC4RMCHR1AVPR1BDYRK1A | |
| SCHEMBL6475167 | 0.91 | DRD2 (0.53) | MC4RMCHR1AVPR1B | |
| SCHEMBL6475480 | 0.89 | MAOB (0.51) | MC4RMCHR1 | |
| SCHEMBL6484254 | 0.88 | PDE3B (0.50) | MC4RPDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL6483313 | 0.88 | PDE3B (0.50) | MC4RPDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL6482649 | 0.87 | HRH2 (0.48) | MC4RMCHR1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | claimed |
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-03-20 | — | — | US | claimed |
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | ARG2, MSR1, ARG1 | MC4R 1554/4885MCHR1 2277/4885AVPR1B 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.